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Abstract. A 52-year-old female with metastatic 
glucagonoma secreting lucagon and chromogran- 
in A was treated with the somatostatin analogue 
octreotide for 2 years without any additional tu- 
mor-reducing interventions. Before therapy plasma 
glucagon was above 8 gg/1 (normal <0.2) and 
within 2 days 3 x200 gg octreotide daily sup- 
pressed plasma glucagon to 2.2-2.5 gg/1. Concomi- 
tantly, chromogranin A dropped from 0.85 rag/1 
(normal <0.1) to 0.2. After 3 weeks the preexisting 
disabling necrolytic migratory erythema had van- 
ished completely, and weight loss was temporarily 
stopped. During therapy chromogranin A and 
plasma glucagon rose, exceeding pretreatment lev- 
els after 3 and 14 months, respectively. After 1 year 
the erythema recurred, responding only transiently 
to increasing doses of octreotide. The patient died 
after 2 years of therapy of tumor cachexy despite 
very high doses of octreotide (4 x 600 gg/day). 
Throughout treatment octreotide did not prevent 
tumor growth, as demonstrated by computed to- 
mography and sonography. Determination of im- 
munoreactive glucagon before and during oc- 
treotide therapy in fractions of plasma samples 
subjected to gel chromatography revealed a reduc- 
tion in the ratio of glucagon to preproglucagon 
from 1.83 (before) to 0.56 (during therapy), indicat- 
ing inhibition of posttranslational processing of 
preproglucagon by octreotide, thereby reducing 
circulating bioactive glucagon. In summary, oc- 
Abbreviations: CGA=chromogranin A; IRG=immunoreac- 
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treotide induced a remission of clinical symptoms 
by inhibiting posttranslational conversion of pre- 
proglucagon to glucagon but did not prevent u- 
mor growth. Therefore, octreotide is a valuable 
therapy for rapid relief of clinical symptoms, there- 
by improving the possibilities for other tumor-re- 
ducing therapies. 
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Glucagonomas are rare tumors of the pancreatic 
alpha cells, with fewer than 150 patients reported 
[13]. Whereas the combination of the clinical symp- 
toms (necrolytic migratory erythema, hyper- 
glycemia, normochromic normocytic anemia, and 
weight loss) are typical for a glucagonoma and thus 
have been termed glucagonoma syndrome [5], the 
symptoms are rather unspecific when considered 
individually. This often delays correct diagnosis 
until the tumor has progressed to a considerable 
size, with local invasion and liver metastases being 
a common finding [13]. Complete surgical removal 
of the tumor cannot be achieved in most patients, 
and chemotherapy is frequently ineffective [9, 13, 
18]. Recently somatostatin and its long-acting ana- 
logue octreotide (OC) have been introduced for 
conservative management of endocrine-active gas- 
trointestinal tumors. So far five patients with 
glucagonoma h ve been treated with OC for 1 year 
or longer [1, 21, 30]. Interestingly, all patients expe- 
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rienced clinical improvement, despite elevated 
glucagon plasma levels during therapy. We report 
our experiences in the long-term treatment of a 
patient with malignant glucagonoma and propose 
a mechanism by which OC induces clinical remis- 
sion of symptoms. 
Case report 
In a 51-year-old white woman complaining of epi- 
gastric pain abdominal ultrasound and computed 
tomography identified a tumor in the pancreatic 
head and metastases in the liver. Simultaneously 
hyperglycemia, weight loss of 6 kg, and the onset of 
a cutaneous rash was noted. Laparatomy (Fig. 1, 
day 122) revealed a tumor (3 x 4 cm) in the pancre- 
atic head and several metastases in the right and 
left lobes of the liver. Except for a small nodule on 
the surface of left lobe of the liver no tissue was 
removed. Histological and immunocytochemical 
examination revealed a pancreatic alpha cell tumor 
staining positive for glucagon and chromogranin A 
(CGA). Glucagon plasma levels, determined post- 
operatively, were extremely elevated (7.8-8.3 gg/1). 
Thereafter the patient's condition gradually deteri- 
orated, with further weight loss (Fig. 1F), develop- 
ment of normochromic normocytic anemia 
(Fig. 1C) and rapid spreading of the rash. In July 
1990 the patient was referred to our clinic for fur- 
ther therapy. 
We saw a mildly depressed lady of normal 
weight (height 164 cm, weight 59.5 kg) with dissem- 
inated desquamating pruritic rash, most pro- 
nounced in areas of mechanical friction. Severe 
cheilitis and stomatitis prevented intake of regular 
food. Histological examination of a skin biopsy 
confirmed necrolytic migratory erythema. After de- 
tailed information about the nature of the disease 
the patient rejected laparatomy for palliative re- 
duction of tumor mass as well as any form of cyto- 
static chemotherapy but gave written informed 
consent o participate in the German Multicenter 
Trial for Therapy of Endocrine Gastrointestinal 
Tumors with Octreotide which had been approved 
by the Ethics Committee of the Philipps-Universi- 
ty, Marburg, Germany (study center). After obtain- 
ing baseline data, including an oral glucose toler- 
ance test revealing nonsuppressible glucagon levels, 
therapy with OC (Sandostatin, Sandoz, Niirnberg, 
Germany) was initiated on day 1 (Fig. 1E). To 
avoid hypoglycemic reactions, OC was given in in- 
cremental doses (3x50lag/day for 3 days, 
3 x 100 gg/day for 3 days) until the maintenance 
dose of 3 x 200 lag/day was reached. 
Pathological laboratory findings on admission 
were as follows (normal values in parentheses): 
hemoglobin 98 g/1 (120-160), fasting blood glucose 
11.7 mmol/1 (<5.55), glycosylated hemoglobin 
10.4% (<8%), glucagon 8.43 gg/1 (<0.2), insulin 
21 mIU/1, C peptide 5.0 ng/ml, CGA 0.85 mg/1 
(< 0.1). All other investigations revealed normal 
values. 
Material and methods 
Blood samples were obtained in chilled tubes 
containing EDTA and 500 U aprotinin (Trasylol, 
Bayer, Leverkusen, Germany) per milliliter of 
blood. After centrifugation at 4°C and 2500 rpm 
for 20 min, the plasma was immediately separated 
and stored at -20°C until assayed. Plasma sam- 
ples were analyzed using a commercially available 
assay for glucagon employing a rabbit anti- 
glucagon antibody (100% cross-reaction with pre- 
proglucagon and proglucagon) and polyethyleng- 
lycol for separation of bound from free (Serono 
Diagnostica, Freiburg, Germany). Intra- and in- 
terassay (n = 6) coefficients of variation were 5.6% 
and 7.8%, respectively. 
CGA was determined in serum samples with an 
immunoluminometric assay described elsewhere 
[4]. Intra- and interassay coefficients of variation 
were 5.5% and 12.6%, respectively. 
Plasma samples were placed on polyacrylamide 
gel (Bio-Gel P-30, Bio-Rad Laboratories, Rich- 
mond, CA, USA), column size 1 x 50 cm, and elut- 
ed with 0.2 mol/1 glycine (Sigma Diagnostics, St. 
Louis, MO, USA) containing 0.25% human serum 
albumin (Sigma Diagnostics), 500 U aprotinin/1, 
and 1% normal sheep serum, pH 8.8, at 4°C [7, 24, 
25]. The flow rate was 5 ml/h. The column was 
calibrated with dextran blue, ribonuclease A, cy- 
tochrome c, cobalamine (all Sigma Diagnostics) 
and tracer amounts of ~25I-labeled C peptide and 
125I-labeled insulin. 125I-labeled glucagon was 
added to each run. Eluates of 1.5 ml were collected, 
counted for radioactivity, and analyzed for 
glucagon immunoreactivity (IRG). IRG was deter- 
mined using antiserum 30 K (kindly provided by 
Prof. R.H. Unger) and dextran coated charcoal sep- 
aration following previously published methods 
[10]. All samples were analyzed in one assay. The 
coefficient of variation was 11.4%. 
Scintigraphy with labeled OC was performed 
after interruption of OC therapy for 8 days (days 
65-73, Fig. 1E) The radiopharmaceutical [ll ln- 
DTPA-D-Phel]-OC and imaging procedure have 
been described previously [3, 15]. 
The size of the primary tumor in the head of the 
pancreas and a reference metastasis were deter- 
mined by computed tomography and ultrasonog- 
raphy. The largest diameters of three axes vertical 
to each other were determined, multiplied, and ex- 
pressed as tumor size in milliliters. Computed to- 
mography and ultrasonography performed before 
day 5 were made with different equipment, but pic- 
tures and scans were available for evaluation. 
Resu l ts  
Clinical course 
Throughout herapy OC did not inhibit tumor 
growth (Fig. 1A). Due to compression of the duo- 
denum between the primary tumor and a large liver 
metastasis causing postprandial vomiting and 
cholestasis laparatomy with gastrojejunostomy 
and a biliodigestive anastomosis had to be per- 
formed on day 422 of therapy. 
Plasma glucagon levels were grossly elevated 
before therapy and dropped to 2.2-2.5 Hg/1 within 2 
days after initiation of OC therapy (Fig. 1E). When 
OC was discontinued for 8 days, a rapid increase 
was observed, with the peak (9.39 gg/1) exceeding 
pretreatment levels. After reinstitution of OC treat- 
ment, the glucagon plasma levels were suppressed 
to the previous treatment range. 
During the initial phase of OC treatment serum 
CGA was suppressed to 0.2-0.5mg/1 (Fig. 1D). 
CGA increased rapidly to above pretreatment lev- 
els during OC discontinuation and was quickly 
suppressed when OC was reinstituted. From then 
on a constant slow rise in both tumor products, 
glucagon and CGA, was observed, except for a 
sudden increase in glucagon after 400 days of ther- 
apy, which appears to be related to the rapidly 
growing liver metastasis. 
The severely handicapping necrolytic migrato- 
ry erythema improved within 3 days of OC treat- 
ment and completely resolved after 21 days of ther- 
apy, as did the stomatitis and cheilitis. When thera- 
py was interrupted for 8 days for scintigraphy with 
labeled OC, early signs of the rash were noticed, 
which quickly responded to the continuation of 
therapy. On day 140 the patient noticed recurrence 
of the rash, which from then onward waned and 
recurred espite continued therapy with OC. After 
day 400 the rash occurred frequently and improved 
only temporarily in response to increasing OC dos- 
es (Fig. 1E). On day 562 the necrolytic migratory 
erythema had considerably worsened, requiring 
hospitalization, and did not improve despite inten- 
sified therapy with OC (4 x 600 gg/day). 
After initiation of OC therapy and one package 
of erythrocytes (450 ml) serum hemoglobin concen- 
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Fig. 1. Synopsis of clinical data (tumor size, A; body weight, F; 
Karnofsky index, F) and laboratory data (fasting blood glucose, 
B; haemoglobin, C; serum chromogranin A, D; plasma 
glucagon, E) of the glucagonoma p tient before and during ther- 
apy with OC, which was initiated on day 1 (doses of OC are 
depicted in E). The size of the primary tumor in the pancreatic 
head (circles) and of a reference metastasis in the right liver lobe 
(squares) were determined by ultrasonography (open symbols) 
and computed tomography (solid symbols A). Supplementation 
with erythrocyte concentrates (450ml) is indicated (~, C). 
Where applicable, normal ranges are shaded. Note the logarith- 
mic scales in D and E 
trations showed a rapid increase (Fig. 1C). Hemo- 
globin levels stabilized thereafter in the lower nor- 
mal range. The surgery-related blood loss after day 
422 required transfusions of erythrocytes (2 x 
450 ml). 
Fasting blood glucose worsened uring therapy 
with OC (Fig. 1B). Whereas before treatment with 
OC fasting glucose rarely exceeded 10 mmol/1, dur- 
ing therapy it was usually around 12 mmol/1. The 
oral antidiabetic glibenclamide lowered blood glu- 
cose concentrations but was unable to normalize 
glucose levels. The patient refused insulin therapy 
since this required subcutaneous injections in addi- 
tion to OC. 
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Body weight, which had decreased by more 
than 20% within 7 months, increased slightly with 
initiation of OC therapy, but after 3 months the 
weight loss continued (Fig. 1F). Repeated intermit- 
tent high-caloric parenteral nutrition (>21 kJ per 
day) supplemented with human insulin was unable 
to prevent further weight loss. After 2 years of ther- 
apy the patient died of cachexy, with a body weight 
of 38.3 kg. 
In addition to other parameters in Fig. 1, the 
Karnofsky index [14] presents the clinical improve- 
ment induced by OC therapy (Fig. 1F). Within a 
few weeks after initiation of treatment, he patient 
improved remarkably and was able to live at home 
without additional support. After 1 year of therapy 
the symptoms caused by the duodenal stenosis and 
cholestasis initiated a continuous decline in the 
Karnofsky index. Since the patient rejected both 
surgical tumor reduction and any form of chemo- 
therapy, OC therapy was continued after day 450 
despite clinical and laboratory signs of tumor pro- 
gression. 
Side effects 
Throughout the treatment with OC the patient ex- 
perienced slight pain at the injection site lasting for 
several minutes. OC enhanced a preexisting ten- 
dency to loose stools and induced steatorrhea, 
which was not improved by supplementation f 
pancreatic enzymes or treatment with loperamide. 
After 3 months of OC therapy fasting glucose 
serum levels were increased but improved on thera- 
py with glibenclamide. Gall bladder stones did not 
develop. 
Gel chromatography of plasma glucagon 
Gel chromatographic separation with subsequent 
determination f IRG of a plasma sample obtained 
before OC therapy clearly showed three distinct 
peaks, with molecular weights of 3500, 9000, and 
greater than 13 000 daltons (Fig. 2). Analysis of a 
plasma sample obtained when glucagon levels were 
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Fig. 2. Determination of immunoreactive glucagon in plasma 
samples obtained before (0) and during (©) therapy with OC 
submitted to gel chromatography. Fractions 15-25 are pro- 
posed to resemble preproglucagon, fractions 27-33 
proglucagon, and fractions 37-46 glucagon 
suppressed to 2.49 gg/1 after 60 days of OC therapy 
revealed only two peaks of IRG, of 3500 and 
greater than 13 000 daltons (Fig. 2). The ratio of the 
relative amount of IRG in fractions containing the 
different peaks was reversed by OC therapy (Table 
1). In addition, during therapy with OC no substan- 
tial peak for proglucagon was observed. 
Somatostatin scintigraphy 
Figure 3 illustrates the primary tumor in the head 
of the pancreas and its metastasis n the liver 48 h 
after intravenous injection of 320 MBq [t~qn_DT- 
PA-D-Phe~]-OC. Other sites of metastasis were not 
observed. 
Table 1. Relative proportion of IRG of different fractions of plasma samples obtained before 
and during therapy with OC (day 60) after submission to gelchromatography (Fig. 2) 
Fractions Peptide Before therapy During therapy 
(% of IRG) (% of IRG) 
15-25 Preproglucagon 24.5 56.7 
27-33 Proglucagon 9.8 4.7 
37-46 Glucagon 62.6 34.5 
15-46 100 100 
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Fig. 3A, B. Abdominal image in a patient with giucagonoma, 
48 h after injection of nlIn-labeled OC. A Anterior planar im- 
age. Normal uptake of radioactivity in the kidneys and spleen. 
The various hot spots in the liver indicate the presence of metas- 
tasis of the primary tumor, which is located directly medial to 
the upper pole of the right kidney. B Three-dimensional recon- 
struction. Liver background has been reduced. The kidneys and 
spleen are visualized. The primary tumor in the head of the 
pancreas and its metastasis n the liver are also visualized. 1, 
Primary tumor in the pancreatic head; 2, metastasis in the right 
lobe of the liver; 3, metastasis n the left lobe of the liver; 4, 
spleen; 5, left kidney; 6, right kidney 
Discussion 
The long-acting somatostatin analogue OC has 
been used in a variety of endocrine tumors for sup- 
pression of hormone production and secretion [8, 
17], but few patients with glucagonoma h ve been 
studied uring long-term therapy with somatostat- 
in alone [1, 21, 30]. In our patient OC initially in- 
duced a lasting remission of clinical symptoms but 
did not inhibit tumor growth. The remarkably 
quick resolution of the previously disabling ne- 
crolytic migratory erythema improved the well-be- 
ing of the patient within few days. Furthermore, the 
hemoglobin concentration was normalized without 
additional therapy within 4 weeks of therapy. This 
patient gained 1 year of high quality of life. 
The mechanism of OC-induced remission of 
symptoms in patients with glucagonoma is still un- 
clear. Certainly the sustained suppression of 
glucagon plasma levels compared to pretreatment 
concentrations plays an important role. Neverthe- 
less, during therapy glucagon plasma levels are still 
elevated, in our patient exceeding the upper normal 
limit tenfold, and glucagon plasma concentrations 
rose despite continuous treatment with OC. 
Glucagon immunoreactivity is heterogeneous in 
human plasma [11, 12, 26]. In addition to glucagon, 
plasma of normal subjects and of patients with 
glucagonoma contains proglucagon [6, 7, 11, 12, 19, 
24, 25, 28, 29], a 9000-dalton protein devoid of 
glucagon bioactivity [20] formerly termed "large" 
glucagon immunoreactivity, and preproglucagon 
(a 180 amino acid protein) [12, 24, 25, 28] previous- 
ly referred to as "big" plasma glucagon, which all 
cross-react with the anti-glucagon antibody K30 
[27, 29] specific for the carboxyl-terminal region of 
glucagon [2]. In the present study determination f 
IRG in plasma subjected to gel chromatography 
clearly revealed three distinct immunoreactive 
glucagon species in the molecular weight range of 
3500, 9000, and larger than 13 000 daltons, resem- 
bling glucagon, preglucagon, and preproglucagon, 
respectively. During therapy with OC a consider- 
able shift from 3500-dalton glucagon towards pre- 
proglucagon was observed. Therefore, we speculate 
that OC inhibits preferentially posttranslational 
conversion of biologically inactive high molecular 
weight precursors of glucagon to bioactive 3500- 
dalton glucagon. Thus, determination of im- 
munoreactive glucagon in plasma does not reflect 
the true suppression of bioactive glucagon. This 
explains the discrepancy between high plasma 
glucagon concentrations and the vanishing symp- 
toms during OC therapy in our patient and other 
cases [22]. Furthermore, if somatostatin and its 
analogue OC interfere only with posttranslational 
processing of preproglucagon but do not inhibit 
gene expression, tumor proliferation might not be 
prevented, as was shown in this and other patients. 
The slow but constant decrease in body weight 
clearly shows that OC is not able to reverse the 
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catabolism. In addition to glucagon, which remains 
elevated uring OC therapy, even when bioinactive 
precursors are accounted for, other factors might 
add to the catabolism. The weight loss may also be 
related to loose stools and steatorrhea induced by 
OC, which has been reported before [1]. In addition 
to suppression of pancreatic exocrine function [8], 
other factors such as reduced gastrointestinal re- 
sorption and splanchnic blood flow [16] appear to 
contribute to the steatorrhea, since it did not re- 
spond to orally administered pancreatic enzymes in 
our patient. Furthermore, hyperglycemia was wors- 
ened by OC, which is most likely due to suppres- 
sion of insulin secretion (data not shown). Thus, 
less glucose is metabol ized and more glucose lost 
with urine, enhancing the catabolism. 
This is the first g lucagonoma reported to 
secrete CGA [13]. CGA is produced by a variety of 
endocrine neoplasm or adenomas and has proven 
to be a useful marker  for such tumors [23]. In our 
patient, serum CGA demonstrated better sensitivi- 
ty in the reflection of tumor activity than plasma 
glucagon levels. Therefore CGA might be useful as 
an addit ional tumor marker  in glucagonomas, es- 
pecially when considering the change in p lasma 
IRG induced by OC, which does not reflect true 
tumor  activity but merely changing posttransla- 
tional processing of glucagon precursors. 
Scintigraphy with labeled somatostat in has 
confirmed the location of the pr imary tumor in the 
pancreatic head and the presence of several metas- 
tases in the liver. Metastases at other locations 
were not detected by scintigraphy. With hindsight, 
this was confirmed by the clinical course, since no 
metastases were identified elsewhere. This adds fur- 
ther evidence to the usefulness of scintigraphy with 
labeled somatostat in or its analogue OC, especially 
when surgical reduction of tumor  mass is being 
considered. 
In summary,  we conclude that OC is a valuable 
therapy for quick relief of symptoms in patients 
with g lucagonoma syndrome but does not prevent 
tumor  growth. Furthermore,  this investigation in- 
dicates that OC inhibits posttranslat ional conver- 
sion of biologically glucagon precursors to bioac- 
tive glucagon. 
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